Cantor Fitzgerald Maintains $85.0 Target Price per Share On Zoetis (ZTS), Maintains “Buy” Rating; Arrow Financial (AROW) Has 3 Sentiment

Among 21 analysts covering Zoetis Inc (NYSE:ZTS), 15 have Buy rating, 0 Sell and 6 Hold. Therefore 71% are positive. Zoetis Inc has $82.0 highest and $48 lowest target. $66.41’s average target is -8.20% below currents $72.34 stock price. Zoetis Inc had 64 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Zoetis Inc. (NYSE:ZTS) has “Buy” rating given on Thursday, September 29 by Bank of America. Hilliard Lyons initiated Zoetis Inc. (NYSE:ZTS) on Tuesday, June 20 with “Buy” rating. The stock of Zoetis Inc. (NYSE:ZTS) earned “Outperform” rating by Cowen & Co on Thursday, December 15. The stock of Zoetis Inc. (NYSE:ZTS) has “Buy” rating given on Friday, May 26 by C.L. King. As per Thursday, December 15, the company rating was reinitiated by Piper Jaffray. The firm has “Equal-Weight” rating given on Thursday, August 4 by Barclays Capital. Morgan Stanley maintained the stock with “Equal-Weight” rating in Friday, November 3 report. The stock has “Buy” rating by Cowen & Co on Thursday, August 24. Cowen & Co maintained Zoetis Inc. (NYSE:ZTS) rating on Friday, October 13. Cowen & Co has “Buy” rating and $70.0 target. The company was initiated on Thursday, February 4 by Credit Suisse.

Arrow Financial Corporation operates as the bank holding firm for Glens Falls National Bank and Trust Company, and Saratoga National Bank and Trust Company that provide commercial and consumer banking, and financial services and products. The company has market cap of $483.73 million. The companyÂ’s deposit products include demand deposits, interest-bearing checking accounts, savings deposits, and time deposits. It has a 17.44 P/E ratio. The Company’s lending activities comprise commercial loans, such as term loans, time notes, and lines of credit for working capital needs; commercial construction and land development loans; commercial real estate loans to finance real estate purchases, refinancing, expansions, and improvements to commercial properties; consumer installment loans to finance personal expenditures, personal lines of credit, and overdraft protection; and residential real estate loans.

The stock decreased 1.28% or $0.45 during the last trading session, reaching $34.75. About 10,253 shares traded. Arrow Financial Corporation (AROW) has risen 17.97% since December 27, 2016 and is uptrending. It has outperformed by 1.27% the S&P500.

Arrow Financial Corp holds 11.73% of its portfolio in Arrow Financial Corporation for 1.44 million shares. Adirondack Trust Co owns 5,160 shares or 0.14% of their US portfolio. Moreover, Trust Co Of Vermont has 0.12% invested in the company for 35,523 shares. The Vermont-based Maple Capital Management Inc. has invested 0.06% in the stock. Walthausen & Co. Llc, a New York-based fund reported 18,035 shares.

Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $17,550 activity.

The stock increased 0.49% or $0.35 during the last trading session, reaching $72.34. About 792,134 shares traded. Zoetis Inc. (NYSE:ZTS) has risen 29.89% since December 27, 2016 and is uptrending. It has outperformed by 13.19% the S&P500.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. The company has market cap of $35.25 billion. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It has a 38.09 P/E ratio. The firm also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products.